Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adipic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | FABP3 | P05413 | 7/20 | 0.48 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azelaic Acid SCHEMBL4279611 | 0.96 | CA1 (0.55) | CA1FFAR3HDAC3HDAC1HDAC2 | |
| Sebacic Acid SCHEMBL4274063 | 0.96 | CA1 (0.55) | CA1FFAR3HDAC3HDAC1HDAC2 | |
| SCHEMBL5915019 | 0.96 | CA1 (0.55) | CA1FFAR3HDAC3HDAC1HDAC2 | |
| Octanedioate SCHEMBL4275256 | 0.96 | CA1 (0.55) | CA1FFAR3HDAC3HDAC1HDAC2 | |
| Adipic Acid SCHEMBL5146021 | 0.92 | CA1 (0.58) | CA1FFAR3HDAC3HDAC1HDAC2 | |
| Adipic Acid SCHEMBL11050745 | 0.92 | CA1 (0.58) | CA1FFAR3HDAC3HDAC1HDAC2 | |
| Adipic Acid SCHEMBL9820842 | 0.92 | CA1 (0.58) | CA1FFAR3HDAC3HDAC1HDAC2 | |
| Adipic Acid SCHEMBL4369554 | 0.92 | CA1 (0.58) | CA1FFAR3HDAC3HDAC1HDAC2 | |
| Adipic Acid SCHEMBL1194225 | 0.92 | CA1 (0.58) | CA1FFAR3HDAC3HDAC1HDAC2 | |
| Glutarate SCHEMBL3142994 | 0.92 | CA1 (0.58) | CA1FFAR3HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4604912-A1 | NATURAL SUBSTANCE-BASED HAIR DYEING METHOD | Henkel AG & Co. KGaA (DE) | 2025-08-27 | — | — | EP | claimed |
| WO-2024083438-A1 | NATURAL SUBSTANCE-BASED HAIR DYEING METHOD | HENKEL AG & CO. KGAA (DE) | 2024-04-25 | — | — | WO | claimed |
| EP-3596545-B1 | SILVER-CONTAINING COMPOSITIONS CONTAINING CELLULOSIC POLYMERS AND USES | EASTMAN KODAK CO (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3688773-A1 | SILVER-CONTAINING NON-AQUEOUS COMPOSITION CONTAINING CELLULOSIC POLYMERS | Eastman Kodak Company (US) | 2020-08-05 | — | — | EP | claimed |
| EP-3596545-A1 | SILVER-CONTAINING COMPOSITIONS CONTAINING CELLULOSIC POLYMERS AND USES | Eastman Kodak Company (US) | 2020-01-22 | — | — | EP | claimed |
| US-10412970-B2 | Method of making and using a methyl methacrylate/silver dispersion | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2019-09-17 | — | — | US | claimed |
| US-10370515-B2 | Silver-containing non-aqueous composition containing cellulosic polymers | EASTMAN KODAK COMPANY (US) | 2019-08-06 | — | — | US | claimed |
| US-20190092923-A1 | SILVER-CONTAINING NON-AQUEOUS COMPOSITION CONTAINING CELLULOSIC POLYMERS | BANK OF AMERICA, N.A., AS AGENT | 2019-03-28 | — | — | US | claimed |
| WO-2019060167-A1 | SILVER-CONTAINING NON-AQUEOUS COMPOSITION CONTAINING CELLULOSIC POLYMERS | EASTMAN KODAK COMPANY (US) | 2019-03-28 | — | — | WO | claimed |
| US-20180343871-A1 | METHOD OF MAKING AND USING A METHYL METHACRYLATE/SILVER DISPERSION | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2018-12-06 | — | — | US | claimed |
| EP-1567101-A2 | PROPHYLACTIC TREATMENT METHODS | NUCFRYST PHARMACEUTICALS CORP. (CA) | 2005-08-31 | — | — | EP | claimed |
| US-20040191329-A1 | Compositions and methods of metal-containing materials | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-09-30 | — | — | US | claimed |
| US-20040110738-A1 | Prophylactic treatment methods | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-06-10 | — | — | US | claimed |
| WO-2004037187-A2 | METAL-CONTAINING MATERIALS, COMPOSITIONS AND METHODS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-05-06 | — | — | WO | claimed |
| WO-2004037186-A2 | PROPHYLACTIC TREATMENT METHODS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2004-05-06 | — | — | WO | claimed |
| EP-0964300-B1 | Black and white thermographic recording material with improved image tone | AGFA GEVAERT (BE) | 2003-07-09 | — | — | EP | claimed |
| US-6211116-B1 | Substantially light-insensitive black and white thermographic recording material with improved image tone | AGFA-GEVAERT (BE) | 2001-04-03 | — | — | US | claimed |
| EP-0964300-A1 | Black and white thermographic recording material with improved image tone | AGFA-GEVAERT N.V. (BE) | 1999-12-15 | — | — | EP | claimed |
| US-4021250-A | PHOTOGRAPHY | FUJI PHOTO FILM CO., LTD. (JA) | 1977-05-03 | — | — | US | claimed |
| US-3997346-A | Method for stabilizing the image of a thermally developable photosensitive material | FUJI PHOTO FILM CO., LTD. (JA) | 1976-12-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370515-B2 | Silver-containing non-aqueous composition containing cellulosic polymers | PRKG1, PRKCB, PRKCA | CA1 1355/4885FFAR3 2963/4885HDAC3 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.